What is the 13F Pro Quality Score for BOLT?

13F Pro ranks Bolt Biotherapeutics, Inc. (BOLT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BOLT's current score at https://13fpro.ai/company/BOLT (free sign-up required for the full ranking).

Which hedge funds own the most BOLT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BOLT include Sofinnova Ventures, RENAISSANCE TECHNOLOGIES, Vivo Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BOLT as soon as new 13F filings post.

Where does 13F Pro source BOLT data?

All Bolt Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Bolt Biotherapeutics, Inc. files with the SEC under CIK 1641281. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BOLT in?

Bolt Biotherapeutics, Inc. (BOLT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BOLT research updated on 13F Pro?

BOLT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Bolt Biotherapeutics, Inc.(BOLT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1641281 BOLT stock profile & AI dashboard →

13F Pro Quality Score

11.3/100

Rank #2,901 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BOLT Scores 11/100

exact factor attribution · 2026-09-11

BOLT's composite is driven by earnings growth, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-1.3 pts

24th pct

Shareholder dilution

-2.0 pts

9th pct

Earnings quality

-4.1 pts

9th pct

Capital efficiency

-4.1 pts

9th pct

Profitability

-6.5 pts

7th pct

Scale

-6.7 pts

5th pct

Free cash flow

-6.7 pts

5th pct

Revenue growth

-9.5 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BOLT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Bolt Biotherapeutics, Inc. (BOLT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BOLT at 11.3/100 on a 32-signal composite quality model, placing it at rank #2,901 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Bolt Biotherapeutics, Inc. reports quarterly revenue of $5.0K, net income of $-7.7M. Top institutional holders of BOLT by reported 13-F value include Sofinnova Ventures, RENAISSANCE TECHNOLOGIES, Vivo Capital, based on the most recent SEC filings. BOLT trades on the Nasdaq exchange and files with the SEC under CIK 1641281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bolt Biotherapeutics, Inc. directly from SEC EDGAR. Bolt Biotherapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 27 since 2022, currently 11.3 — a declining long-term trajectory across 20 quarterly and live scoring snapshots.

Revenue

Q2 2026

$5.0K

Net Income

Q2 2026

$-7.7M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+0.1% YoY

$7.7MFY 2025

FY22 $5.7MFY23 $7.9MFY24 $7.7MFY25 $7.7M

Net Income

+47.1% YoY

$-33.4MFY 2025

FY22 $-88.1MFY23 $-69.2MFY24 $-63.1MFY25 $-33.4M

Operating Income

+50.6% YoY

$-36.1MFY 2025

FY22 $-90.3MFY23 $-76.2MFY24 $-73.0MFY25 $-36.1M

EPS (Diluted)

-979.9% YoY

$-17.85FY 2025

FY22 $-0.12FY23 $-0.09FY24 $-1.65FY25 $-17.85

Total Assets

-43.0% YoY

$56.7MFY 2025

FY22 $227.8MFY23 $159.8MFY24 $99.6MFY25 $56.7M

Op. Cash Flow

+35.0% YoY

$-39.9MFY 2025

FY22 $-76.5MFY23 $-69.5MFY24 $-61.3MFY25 $-39.9M

Free Cash Flow

+34.9% YoY

$-39.9MFY 2025

FY22 $-78.5MFY23 $-69.7MFY24 $-61.3MFY25 $-39.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$7.7M +0.1%	$7.7M -2.4%	$7.9M +37.5%	$5.7M +354.7%	$1.3M +445.5%	$231.0K
Net Income	$-33.4M +47.1%	$-63.1M +8.8%	$-69.2M +21.5%	$-88.1M +10.6%	$-98.6M -62.3%	$-60.7M
Operating Income	$-36.1M +50.6%	$-73.0M +4.1%	$-76.2M +15.6%	$-90.3M +2.7%	$-92.8M -88.7%	$-49.2M
EPS (Diluted)	$-17.85 -979.9%	$-1.65 -1706.6%	$-0.09 +22.5%	$-0.12 +20.5%	$-0.15	—
Total Assets	$56.7M -43.0%	$99.6M -37.6%	$159.8M -29.9%	$227.8M -26.0%	$307.7M +561.2%	$46.5M
Operating Cash Flow	$-39.9M +35.0%	$-61.3M +11.8%	$-69.5M +9.1%	$-76.5M -34.1%	$-57.1M -20.6%	$-47.3M
Free Cash Flow	$-39.9M +34.9%	$-61.3M +12.0%	$-69.7M +11.1%	$-78.5M -32.1%	$-59.4M -17.5%	$-50.6M

Get alerted when BOLT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bolt Biotherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BOLT

Sofinnova Ventures Inc
$530.2K137,721 sh
RENAISSANCE TECHNOLOGIES LLC
$379.7K98,625 sh
Vivo Capital, LLC
$278.8K72,414 sh
CITADEL ADVISORS LLC
$219.1K56,903 sh
T3 Companies, LLC
$146.3K38,000 sh
Board of Trustees of The Leland Stanford Junior University
$138.5K35,977 sh
PFIZER INC
$133.8K31,305 sh
Lynx1 Capital Management LP
$118.6K30,800 sh
NANO CAP NEW MILLENNIUM GROWTH FUND L P
$105.9K27,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$73.6K19,119 sh

Fund	Value	Shares
Sofinnova Ventures Inc	$530.2K	137,721
RENAISSANCE TECHNOLOGIES LLC	$379.7K	98,625
Vivo Capital, LLC	$278.8K	72,414
CITADEL ADVISORS LLC	$219.1K	56,903
T3 Companies, LLC	$146.3K	38,000
Board of Trustees of The Leland Stanford Junior University	$138.5K	35,977
PFIZER INC	$133.8K	31,305
Lynx1 Capital Management LP	$118.6K	30,800
NANO CAP NEW MILLENNIUM GROWTH FUND L P	$105.9K	27,500
GEODE CAPITAL MANAGEMENT, LLC	$73.6K	19,119

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BOLT on your watchlist

Track score changes the day Bolt Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BOLT a good stock to buy?

13F Pro's AI-powered analysis of Bolt Biotherapeutics, Inc. (BOLT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BOLT are available on the BOLT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BOLT is classified as a small company.

Which hedge funds own BOLT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BOLT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bolt Biotherapeutics, Inc.'s investment landscape.